Search

Displaying results 2581 - 2590 of 10000 in total
  1. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    [L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]

  2. Drug

    Pancrelipase lipase

    go.drugbank.com/drugs/DB13147
    ApprovedInvestigational

    [A32748] The pancrelipase mixture, including pancrelipase lipase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

    Mixtures: Pancrease Mt 10, Creon 10 Minimicrospheres
  3. Target

    Heat shock protein 105 kDa

    go.drugbank.com/bio_entities/BE0009029
    TargetHumans

    Acts as a nucleotide-exchange factor (NEF) for chaperone proteins HSPA1A and HSPA1B, promoting the release of ADP from HSPA1A/B thereby triggering client/substrate protein release (PubMed:24318877). Prevents the aggregation of denatured ...

    Polypeptides: Heat shock protein 105 kDa
  4. Target

    Tumor susceptibility gene 101 protein

    go.drugbank.com/bio_entities/BE0019070
    TargetHumans

    Component of the ESCRT-I complex, a regulator of vesicular trafficking process. Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs). Mediates the assoc...

    Polypeptides: Tumor susceptibility gene 101 protein
  5. Drug

    Digoxin Immune Fab (Ovine)

    go.drugbank.com/drugs/DB00076
    Approved

    Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.

    Categories: Immunoglobulin G
  6. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … [L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized

  7. Drug

    Bevifimod

    go.drugbank.com/drugs/DB15301
    Investigational

    Bevifimod is under investigation in clinical trial NCT01749787 (Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis).

  8. Drug

    Nomifensine

    go.drugbank.com/drugs/DB04821
    ApprovedWithdrawn

    Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets. … Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia.

  9. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk … Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.

  10. Drug

    Estradiol cypionate

    go.drugbank.com/drugs/DB13954
    ApprovedVet approved

    The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. … [DB00783] is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates